Between disputed claims, unconstitutional payments and the new global push for higher prices, the PBS rebate system sits on increasingly shaky ground. It has delivered access and spending control, and might be more important than ever, given global shifts by US frustration, but it has the appearance of a complete mess.
What next for PBS rebate system amid constitutional breaches, disputed claims, and global pressure?
November 6, 2025 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
Donald Trump announces 'MFN' deals with Lilly and Novo Nordisk and end to 'global freeloading'
November 7, 2025 - - Latest News -
Sanofi employees contribute over 400 volunteer hours to community and environmental causes
November 6, 2025 - - Latest News -
Neuren posts record royalties as DAYBUE sales surpass US$100 million in third quarter
November 6, 2025 - - Australian Biotech -
US Ambassador warns UK risks losing pharma investment unless it pays more for medicines
November 6, 2025 - - Latest News -
Pfizer to continue legal fight as court rejects bid to block Novo Nordisk’s Metsera takeover bid
November 6, 2025 - - Latest News -
What next for PBS rebate system amid constitutional breaches, disputed claims, and global pressure?
November 6, 2025 - - Latest News -
Linda Burney to chair new First Nations Pharmacy Network
November 5, 2025 - - Latest News
